Leonardi, C., Reich, K., Foley, P., Torii, H., Gerdes, S., Guenther, L., . . . Papp, K. (2020). Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials. Dermatol Ther (Heidelb).
Citação norma ChicagoLeonardi, Craig, et al. "Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results From the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials." Dermatol Ther (Heidelb) 2020.
MLA CitationLeonardi, Craig, et al. "Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results From the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials." Dermatol Ther (Heidelb) 2020.